EWTX insider transaction filings
Edgewise Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-17. Screen EWTX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-17 | 4/A | MOORE JOHN R — General Counsel | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2026-08-17 | 4/A | Russell Alan J — Chief Scientific Officer, Director | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2026-08-17 | 4/A | Donovan Joanne M. — CMO | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2026-08-17 | 4/A | Nofi Michael — Chief Financial Officer | Grant/award (A): 48,750 (derivative) @ $0 | EDGAR |
| 2026-08-17 | 4/A | Derakhshan Behrad — Chief Business Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-08-14 | 4 | KOCH KEVIN — President and CEO, Director | Option exercise (M): 17,969 @ $0 · Option exercise (M): 21,875 @ $0 · Sale (S): 8,782 @ $43.64 · Sale (S): 8,276 @ $43.66 · Sale (S): 913 @ $44.33 · Option exercise (M): 17,969 (derivative) @ $0 · +3 more | EDGAR |
| 2026-08-14 | 4 | Derakhshan Behrad — Chief Business Officer | Option exercise (M): 5,781 @ $0 · Option exercise (M): 7,500 @ $0 · Sale (S): 2,171 @ $43.79 · Sale (S): 304 @ $44.50 · Sale (S): 150 @ $44.44 · Sale (S): 2,475 @ $43.70 · +4 more | EDGAR |
| 2026-08-14 | 4 | MOORE JOHN R — General Counsel | Option exercise (M): 5,781 @ $0 · Option exercise (M): 6,718 @ $0 · Sale (S): 2,439 @ $43.81 · Sale (S): 59 @ $44.41 · Sale (S): 99 @ $44.50 · Sale (S): 2,419 @ $43.80 · +4 more | EDGAR |
| 2026-08-14 | 4 | Russell Alan J — Chief Scientific Officer, Director | Option exercise (M): 5,781 @ $0 · Option exercise (M): 7,031 @ $0 · Sale (S): 3,238 @ $43.68 · Sale (S): 2,273 @ $43.68 · Sale (S): 390 @ $44.46 · Option exercise (M): 5,781 (derivative) @ $0 · +3 more | EDGAR |
| 2026-08-14 | 4 | Donovan Joanne M. — CMO | Option exercise (M): 5,781 @ $0 · Option exercise (M): 7,031 @ $0 · Sale (S): 2,839 @ $43.78 · Sale (S): 2,779 @ $43.71 · Sale (S): 104 @ $44.43 · Sale (S): 800 @ $44.52 · +5 more | EDGAR |
| 2026-08-14 | 4 | Nofi Michael — Chief Financial Officer | Grant/award (A): 24,375 (derivative) @ $0 · Grant/award (A): 48,750 (derivative) @ $0 | EDGAR |
| 2026-07-17 | 4 | ROOT JONATHAN D — Director | Grant/award (A): 16,377 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Russell Alan J — Chief Scientific Officer, Director | Option exercise (M): 130,352 @ $0.45 · Option exercise (M): 69,648 @ $0.18 · Sale (S): 130,352 @ $39.41 · Sale (S): 69,648 @ $39.41 · Option exercise (M): 130,352 (derivative) @ $0 · Option exercise (M): 69,648 (derivative) @ $0 | EDGAR |
| 2026-07-01 | 4 | Fox Jonathan C — Director | Grant/award (A): 319 @ $0 | EDGAR |
| 2026-06-17 | 4 | Brege Laura — Director | Grant/award (A): 16,377 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Morris Arlene — Director | Grant/award (A): 16,377 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Thompson Peter A. — Director, 10% owner | Grant/award (A): 16,377 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Martin Christopher Nathan — Director | Grant/award (A): 16,377 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Edris Badreddin — Director | Grant/award (A): 5,619 (derivative) @ $0 · Grant/award (A): 8,188 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Fox Jonathan C — Director | Grant/award (A): 16,377 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | Donovan Joanne M. — CMO | Sale (S): 5,230 @ $31.29 · Option exercise (M): 50,000 @ $7.08 · Sale (S): 50,000 @ $38.57 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Fox Jonathan C — Director | Grant/award (A): 339 @ $0 | EDGAR |
| 2026-04-02 | 4 | Donovan Joanne M. — CMO | Option exercise (M): 28,662 @ $7.08 · Sale (S): 28,662 @ $32.31 · Option exercise (M): 28,662 (derivative) @ $0 | EDGAR |
| 2026-03-31 | 4 | Donovan Joanne M. — CMO | Option exercise (M): 21,338 @ $7.08 · Sale (S): 21,338 @ $32.12 · Option exercise (M): 21,338 (derivative) @ $0 | EDGAR |
| 2026-03-30 | 4 | Donovan Joanne M. — CMO | Sale (S): 9,623 @ $30.98 · Sale (S): 6,735 @ $30.98 | EDGAR |
| 2026-01-23 | 4 | Edris Badreddin — Director | Option exercise (M): 13,690 @ $0.39 · Option exercise (M): 17,236 @ $0.64 · Option exercise (M): 10,463 @ $1.93 · Option exercise (M): 66,477 @ $1.93 · Option exercise (M): 7,605 @ $0.71 · Sale (S): 13,690 @ $29.44 · +9 more | EDGAR |
| 2026-01-05 | 4 | Fox Jonathan C — Director | Grant/award (A): 473 @ $0 | EDGAR |
| 2025-11-24 | 4 | Martin Christopher Nathan — Director | Grant/award (A): 45,150 (derivative) @ $0 | EDGAR |
| 2025-11-13 | 4 | Russell Alan J — Chief Scientific Officer, Director | Option exercise (M): 100,000 @ $0.18 · Sale (S): 100,000 @ $21.12 · Option exercise (M): 100,000 (derivative) @ $0 | EDGAR |
| 2025-11-13 | 4 | Nofi Michael — Chief Financial Officer | Grant/award (A): 43,750 (derivative) @ $0 · Grant/award (A): 262,500 (derivative) @ $0 | EDGAR |
| 2025-11-13 | 4 | Fox Jonathan C — Director | Purchase (P): 10,700 @ $18.64 | EDGAR |
| 2025-10-02 | 4 | Fox Jonathan C — Director | Grant/award (A): 728 @ $0 | EDGAR |
| 2025-08-28 | 4 | Russell Alan J — Chief Scientific Officer, Director | Option exercise (M): 100,000 @ $0.18 · Sale (S): 100,000 @ $14.60 · Option exercise (M): 100,000 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | Blaustein Robert — Chief Development Officer | Grant/award (A): 17,500 (derivative) @ $0 · Grant/award (A): 105,000 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | Derakhshan Behrad — Chief Business Officer | Option exercise (M): 5,781 @ $0 · Sale (S): 2,491 @ $13.39 · Option exercise (M): 5,781 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 · Grant/award (A): 180,000 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | Russell Alan J — Chief Scientific Officer, Director | Option exercise (M): 5,781 @ $0 · Sale (S): 1,907 @ $13.39 · Option exercise (M): 5,781 (derivative) @ $0 · Grant/award (A): 28,125 (derivative) @ $0 · Grant/award (A): 168,750 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | Carruthers R Michael — Chief Financial Officer | Option exercise (M): 5,781 @ $0 · Sale (S): 1,428 @ $13.39 · Option exercise (M): 5,781 (derivative) @ $0 · Grant/award (A): 26,875 (derivative) @ $0 · Grant/award (A): 161,250 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | Donovan Joanne M. — CMO | Option exercise (M): 5,781 @ $0 · Sale (S): 2,862 @ $13.39 · Option exercise (M): 5,781 (derivative) @ $0 · Grant/award (A): 28,125 (derivative) @ $0 · Grant/award (A): 168,750 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | MOORE JOHN R — General Counsel | Option exercise (M): 5,781 @ $0 · Sale (S): 2,098 @ $13.39 · Option exercise (M): 5,781 (derivative) @ $0 · Grant/award (A): 26,875 (derivative) @ $0 · Grant/award (A): 161,250 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | KOCH KEVIN — President and CEO, Director | Option exercise (M): 17,968 @ $0 · Sale (S): 7,972 @ $13.39 · Option exercise (M): 17,968 (derivative) @ $0 · Grant/award (A): 87,500 (derivative) @ $0 · Grant/award (A): 525,000 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Fox Jonathan C — Director | Grant/award (A): 858 @ $0 | EDGAR |
| 2025-06-18 | 4 | Edris Badreddin — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Fox Jonathan C — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Brege Laura — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Morris Arlene — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Thompson Peter A. — Director, 10% owner | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | ROOT JONATHAN D — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-05-07 | 4 | Russell Alan J — Chief Scientific Officer, Director | Option exercise (M): 5,209 @ $0 · Sale (S): 1,551 @ $16.45 · Option exercise (M): 5,209 (derivative) @ $0 | EDGAR |
| 2025-05-07 | 4 | Derakhshan Behrad — Chief Business Officer | Option exercise (M): 5,209 @ $0 · Sale (S): 1,691 @ $16.45 · Option exercise (M): 5,209 (derivative) @ $0 | EDGAR |
| 2025-05-07 | 4 | Carruthers R Michael — Chief Financial Officer | Option exercise (M): 5,209 @ $0 · Sale (S): 1,314 @ $16.45 · Option exercise (M): 5,209 (derivative) @ $0 | EDGAR |
Recent 8-K events — Edgewise Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-16 | 8-K/A | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-13 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-05 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-20 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=EWTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →